A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Public ClinicalTrials.gov record NCT02799095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1
Study identification
- NCT ID
- NCT02799095
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Enrollment
- 243 participants
Conditions and interventions
Conditions
Interventions
- ALKS 4230 Drug
- ALKS 4230 + pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2016
- Primary completion
- Mar 26, 2023
- Completion
- Aug 1, 2023
- Last update posted
- May 20, 2025
2016 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mural Oncology Investigational Site | Denver | Colorado | 80045 | — |
| Mural Oncology Investigational Site | Port Saint Lucie | Florida | 34952 | — |
| Mural Oncology Investigational Site | Tampa | Florida | 33610 | — |
| Mural Oncology Investigational Site | Lexington | Kentucky | 40536 | — |
| Mural Oncology Investigational Site | Boston | Massachusetts | 02215 | — |
| Mural Oncology Investigational Site | Detroit | Michigan | 47201 | — |
| Mural Oncology Investigational Site | Buffalo | New York | 14203 | — |
| Mural Oncology Investigational Site | New York | New York | 10016 | — |
| Mural Oncology Investigational Site | Cleveland | Ohio | 44106 | — |
| Mural Oncology Investigational Site | Dallas | Texas | 75230 | — |
| Mural Oncology Investigational Site | Fairfax | Virginia | 22031 | — |
| Mural Oncology Investigational Site | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02799095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2025 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02799095 live on ClinicalTrials.gov.